RTW:LSE:LSE-RTW Venture Fund Ltd (USD)

COMMON STOCK | Asset Management |

Last Closing

USD 1.515

Change

-0.01 (-0.33)%

Market Cap

USD 51.03B

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

RTW Biotech Opportunities Ltd is a venture capital fund. The fund specializes in directly investing and early-stage. The fund specializes in identifying transformative assets with high growth potential across the life sciences, biopharmaceutical and medical technology sectors. The fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Asset Management

Symbol Name Price(Change) Market Cap
FP:LSE Fondul Proprietatea S.A. GDR

+0.04 (+0.88%)

USD 264.18B
MNTN:LSE Schiehallion Fund Ltd

N/A

USD 83.75B
TMI:LSE Taylor Maritime Investments Lt..

N/A

USD 33.09B
AMIF:LSE Amicorp FS (UK) PLC

N/A

USD 17.95B
USF:LSE US Solar Fund Plc

N/A

USD 14.31B
ICG:LSE Intermediate Capital Group PLC

+22.00 (+0.95%)

USD 5.96B
FCIT:LSE F&C Investment Trust PLC

+16.00 (+1.57%)

USD 5.04B
MNG:LSE M&G Plc

+3.10 (+1.50%)

USD 4.93B
BPT:LSE Bridgepoint Group Plc

+9.20 (+2.46%)

USD 2.90B
JGGI:LSE JP Morgan Global Growth & Inco..

N/A

USD 2.72B

ETFs Containing RTW:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Asset Management) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.26% 68% D+ 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.26% 69% C- 55% F
Trailing 12 Months  
Capital Gain 22.67% 85% B 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.67% 84% B 72% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.44% 17% F 17% F
Dividend Return -7.44% 16% F 17% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.07% 68% D+ 46% F
Risk Adjusted Return -35.30% 15% F 21% F
Market Capitalization 51.03B 98% N/A 81% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.